Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205554 | PMC |
| http://dx.doi.org/10.1016/j.jdin.2025.02.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Commonly recommended moisturising products: effect on transepidermal water loss and hydration in a scar model.
Burns
July 2025
Department of Plastic and Reconstructive Surgery, Royal Adelaide Hospital, 1 Port Rd, Adelaide, South Australia 5000, Australia; Adelaide Medical School, The University of Adelaide, North Tce, Adelaide, South Australia, 5000, Australia.
Background: Moisturizing is a widely recommended and accessible approach to scar management, yet objective evidence supporting the efficacy of commonly used products remains limited. Research suggests that moisturizers may reduce hypertrophic scar activity by normalising transepidermal water loss (TEWL) and enhancing skin hydration.
Aim: This study aimed to provide insights into the effect of generic moisturizers on TEWL and hydration in a scar model, helping clinicians make informed recommendations for scar treatment.
Aim: To comprehensively evaluate the efficacy and safety of non-pharmacological interventions for radiotherapy-induced xerostomia in patients with head and neck cancer.
Methods: A systematic literature search was conducted in PubMed, Embase, the Cochrane Library, and Web of Science for articles published up to March 1, 2025. Three outcome measures were utilized to assess treatment effectiveness: xerostomia, saliva flow rate, and xerostomia-related quality of life.
Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): Basic Therapy, Topical Therapy, and Conventional Systemic Therapy.
Ann Dermatol
August 2025
Department of Dermatology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Background: Atopic dermatitis (AD) is a common skin disease with a wide range of symptoms. Due to the rapidly changing treatment landscape, regular updates to clinical guidelines are needed.
Objective: This study aimed to update the guidelines for the treatment of AD to reflect recent therapeutic advances and evidence-based practices.
Collagen-Based Products in Wound, Skin, and Health Care.
Adv Wound Care (New Rochelle)
July 2025
Department of Surgery, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Collagen, the most abundant structural protein in the human body, plays a vital role in wound healing, tissue repair, and skin integrity. Collagen-based products-ranging from wound dressings, skin substitutes, dental and orthopedic scaffolds, to topical cosmetics and oral supplements-have proliferated rapidly across healthcare and consumer markets. Medical applications leverage collagen's biocompatibility, biodegradability, and scaffold-forming properties to manage chronic wounds, burns, and bone defects, while emerging technologies such as recombinant collagen and phage-integrated dressings target future innovations.
View Article and Find Full Text PDFEmollients to Prevent Pediatric Eczema: A Randomized Clinical Trial.
JAMA Dermatol
July 2025
Centre of Evidence-Based Dermatology, Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, England.
Article Synopsis
- Atopic dermatitis (AD) is a significant health issue for children and can lead to food allergies and asthma, yet few studies have focused on preventative measures like emollient use in infants not at high risk.
- A clinical trial involving 1247 infants assessed whether daily emollient application starting at 9 weeks could lower AD incidence by 24 months compared to a control group that did not use emollients.
- Results showed a reduced AD incidence of 36.1% in the emollient group versus 43.0% in the control group, particularly among infants not at high risk, indicating that emollient use may effectively decrease the likelihood of developing AD.